支气管舒张试验阴性哮喘患者的乙酰甲胆碱激发试验特征及诊断意义
在自我报告医生诊断哮喘的成人中,支气管舒张试验阴性者43.0%乙酰甲胆碱激发试验阳性,其阴性预测值仅57%不足以排除哮喘。激发试验结果随药物减量与时间变化,部分激发试验阴性者仍获临床哮喘诊断。
要点
- 支气管舒张试验阴性不能排除哮喘,阴性预测值仅57%。
- 存在气流受限者激发试验阳性风险更高(OR 1.90)。
- 激发试验结果可随药物减量或时间推移而改变。
核心结论
- 在自我报告医生诊断哮喘的成人中,支气管舒张反应阴性排除哮喘的阴性预测值仅为57%。
- 存在气流受限者激发试验阳性可能性显著增加(OR 1.90;95%CI 1.17-3.04)。
- 激发试验结果可因药物减量或时间推移而改变,部分激发试验阴性者仍获临床哮喘诊断。
研究设计与样本
- 随机数字拨号在加拿大招募自我报告医生诊断哮喘的成人。
- 受试者行支气管舒张试验,结果不诊断哮喘者返回行乙酰甲胆碱激发试验。
- 使用控制药物者减量并在3至6周内行系列激发试验。
- 激发试验阴性(PC20>8 mg/mL)者停药后由呼吸科医生评估,并在6和12个月后复查激发试验。
主要发现
- 500例支气管舒张试验阴性者中,215例(43.0%)激发试验阳性。
- 94例减药者中18例(19.1%)激发试验由阴性转阳性;165例中25例(15.2%)随时间自发转阳。
- 231例激发试验阴性者中,28例(12.1%)随后获呼吸科医生哮喘诊断。
临床怎么用
- 对临床高度怀疑哮喘但支气管舒张试验阴性者,应重复或进行激发试验。
- 存在气流受限者应警惕哮喘可能,激发试验阳性风险更高。
- 解读激发试验结果时需考虑药物减量和时间因素对结果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with a history suggestive of asthma, diagnosis is usually confirmed by spirometry with bronchodilator response (BDR) or confirmatory methacholine challenge testing (MCT). RESEARCH QUESTION: We examined the proportion of participants with negative BDR testing who had a positive MCT (and its predictors) result and characteristics of MCT, including effects of controller medication tapering and temporal variability (and predictors of MCT result change), and concordance between MCT and pulmonologist asthma diagnosis. STUDY DESIGN AND METHODS: Adults with self-reported physician-diagnosed asthma were recruited by random-digit dialing across Canada. Subjects performed spirometry with BDR testing and returned for MCT if testing was nondiagnostic for asthma. Subjects on controllers underwent medication tapering with serial MCTs over 3 to 6 weeks. Subjects with a negative MCT (the provocative concentration of methacholine that results in a 20% drop in FEV1 [PC20] > 8 mg/mL) off medications were examined by a pulmonologist and had serial MCTs after 6 and 12 months. RESULTS: Of 500 subjects (50.5 ± 16.6 years old, 68.0% female) with a negative BDR test for asthma, 215 (43.0%) had a positive MCT. Subjects with prebronchodilator airflow limitation were more likely to have a positive MCT (OR, 1.90; 95% CI, 1.17-3.04). MCT converted from negative to positive, with medication tapering in 18 of 94 (19.1%) participants, and spontaneously over time in 25 of 165 (15.2%) participants. Of 231 subjects with negative MCT, 28 (12.1%) subsequently received an asthma diagnosis from a pulmonologist. INTERPRETATION: In subjects with a self-reported physician diagnosis of asthma, absence of bronchodilator reversibility had a negative predictive value of only 57% to exclude asthma. A finding of spirometric airflow limitation significantly increased chances of asthma. MCT results varied with medication taper and over time, and pulmonologists were sometimes prepared to give a clinical diagnosis of asthma despite negative MCT. Correspondingly, in patients for whom a high clinical suspicion of asthma exists, repeat testing appears to be warranted.
引用
- Selvanathan J, Aaron SD, Sykes JR, et al. Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis. Chest. 2020. PMID: 32298731. doi:10.1016/j.chest.2020.03.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。